IDH2 and glioblastoma: In conclusion, GBM’s dismal prognosis is a consequence of its aggressive histopathological features compounded by a complex array of molecular mutations, including EGFR amplification/mutation, PTEN loss, TP53 mutation, TERT promoter mutations, and occasional IDH mutations.